psychoneuro 2008; 34(1): 24-28
DOI: 10.1055/s-2008-1061490

© Georg Thieme Verlag Stuttgart · New York

Zerebralparese - Klassifikation und Therapie

Cerebral palsy - Classification and therapyUrban M. Fietzek1 , Steffen Berweck2
  • 1Abt. Neurologie und klinische Neurophysiologie, Neurologisches Krankenhaus München(Ärztliche Leitung: Prof. Dr. A. Ceballos-Baumann)
  • 2Abt. für Pädiatrische Neurologie und Entwicklungsneurologie, Dr. von Haunersches Kinderspital der Universität München(Leiter: Prof. Dr. F. Heinen)
Further Information

Publication History

Publication Date:
27 February 2008 (online)

Zerebralparesen sind die häufigste Ursache einer spastischen Bewegungsstörung im Kindesalter. Der Artikel stellt aktuelle pathophysiologische Konzepte zur Zerebralparese dar und gibt einen Überblick über die interdisziplinären Behandlungsmöglichkeiten der motorischen Störung. Insbesondere wird auf die funktionellen Therapien und die Behandlung mit Botulinumtoxin eingegangen.

Cerebral palsy is the most common etiology of a spastic movement disorder in childhood. The present paper gives an introduction to the classification, the phenomenology, the diagnosis and current pathophysiological concepts of the cerebral palsies. It focusses on the interdisciplinary therapy approach of the motor disorder, especially on the functional therapies and the treatment with botulinum toxin.


  • 1 Ackman JD, Russman BS, Thomas SS. et al. . Comparing botulinum toxin A with casting for treatment of dynamic equinus in children with cerebral palsy.  Dev Med Child Neurol. 2005;  47 620-627
  • 2 Albright AL.. Intrathecal baclofen in cerebral palsy movement disorders.  J Child Neurol. 1996;  11 29-35
  • 3 Andersson C, Grooten W, Hellsten M. et al. . Adults with cerebral palsy: walking ability after progressive strength training.  Dev Med Child Neurol. 2003;  45 220-228
  • 4 Ashwal S, Russman BS, Blasco PA. et al. . Practice parameter: diagnostic assessment of the child with cerebral palsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.  Neurology. 2004;  62 851-863
  • 5 Baker R, Jasinski M, Maciag-Tymecka I. et al. . Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study.  Dev Med Child Neurol. 2002;  44 666-675
  • 6 Barwood S, Baillieu C, Boyd R. et al. . Analgesic effects of botulinum toxin A: a randomized, placebo-controlled clinical trial.  Dev Med Child Neurol. 2000;  42 116-121
  • 7 Berweck S, Feldkamp A, Francke A. et al. . Sonography-guided injection of botulinum toxin A in children with cerebral palsy.  Neuropediatrics. 2002;  33 221-223
  • 8 Berweck S, Schroeder AS, Fietzek UM, Heinen F.. Sonography-guided injection of botulinum toxin in children with cerebral palsy.  Lancet. 2004;  363 249-250
  • 9 Blundell SW, Shepherd RB, Dean CM. et al. . Functional strength training in cerebral palsy: a pilot study of a group circuit training class for children aged 4-8 years.  Clin Rehabil. 2003;  17 48-57
  • 10 Bodkin AW, Baxter RS, Heriza CB.. Treadmill training for an infant born preterm with a grade III intraventricular hemorrhage.  Phys Ther. 2003;  83 1107-1118
  • 11 Campbell WM, Ferrel A, McLaughlin JF. et al. . Long-term safety and efficacy of continuous intrathecal baclofen.  Dev Med Child Neurol. 2002;  44 660-665
  • 12 Corry IS, Cosgrove AP, Duffy CM. et al. . Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial.  J Pediatr Orthop. 1998;  18 304-311
  • 13 Corry IS, Cosgrove AP, Walsh EG. et al. . Botulinum toxin A in the hemiplegic upper limb: a double-blind trial.  Dev Med Child Neurol. 1997;  39 185-193
  • 14 Cosgrove AP, Graham HK.. Botulinum toxin A prevents the development of contractures in the hereditary spastic mouse.  Dev Med Child Neurol. 1994;  36 379-385
  • 15 Crothers B, Paine RS.. Natural History of Cerebral Palsy. Cambridge: Harvard University Press 1959
  • 16 Damiano DL.. Activity, activity, activity: rethinking our physical therapy approach to cerebral palsy.  Phys Ther. 2006;  86 1534-1540
  • 17 Dodd KJ, Foley S.. Partial body-weight-supported treadmill training can improve walking in children with cerebral palsy: a clinical controlled trial.  Dev Med Child Neurol. 2007;  49 101-105
  • 18 Dodd KJ, Taylor NF, Graham HK.. A randomized clinical trial of strength training in young people with cerebral palsy.  Dev Med Child Neurol. 2003;  45 652-657
  • 19 Elbert T, Rockstroh B, Bulach D. et al. . Die Fortentwicklung der Neurorehabilitation auf verhaltensneurowissenschaftlicher Grundlage. Beispiel Constraint-induced-Therapie.  Nervenarzt. 2003;  74 334-342
  • 20 Eliasson AC, Krumlinde-Sundholm L, Shaw K, Wang C.. Effects of constraint-induced movement therapy in young children with hemiplegic cerebral palsy: an adapted model.  Dev Med Child Neurol. 2005;  47 266-275
  • 21 Eyre JA, Miller S, Ramesh V.. Constancy of central conduction delays during development in man: investigation of motor and somatosensory pathways.  J Physiology. 1991;  434 441-452
  • 22 Fehlings D, Rang M, Glazier J, Steele C.. An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy.  J Pediatr. 2000;  137 331-337
  • 23 Flett PJ, Stern LM, Waddy H. et al. . Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy.  J Paediatr Child Health. 1999;  35 71-77
  • 24 Fuchs A, Doderlein L.. Orthopädietechnik und ICP: Aktuelle Versorgungen und Trends in der Orthopädietechnik bei Patienten mit infantiler Zerebralparese.  Orthopade. 2004;  33 1173-1182
  • 25 Heinen F, Molenaers G, Fairhurst. et al. . European consensus table 2006 on botulinum toxin for children with cerebral palsy.  Eur J Paediatr Neurol. 2006;  10 215-225
  • 26 Jongerius PH, Rotteveel JJ, van Limbeek J. et al. . Botulinum toxin effect on salivary flow rate in children with cerebral palsy.  Neurology. 2004;  63 1371-1375
  • 27 Koman LA, Mooney JF, Smith BP. et al. . Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group.  J Pediatr Orthop. 2000;  20 108-115
  • 28 Little WJ.. On the influence of abnormal parturition, difficult labours, premature birth, and asphyxia neonatorum, on the mental and physical condtion of the child, especially in relation to deformities. (Originally published 1862).  Cerebral Palsy Bulletin. 1958;  1 5-36
  • 29 Lowe K, Novak I, Cusick A.. Low-dose/high-concentration localized botulinum toxin A improves upper limb movement and function in children with hemiplegic cerebral palsy.  Dev Med Child Neurol. 2006;  48 170-175
  • 30 Mahrhold S, Rummel A, Bigalke H. et al. . The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves.  FEBS Lett. 2006;  580 2011-2014
  • 31 Mall V, Heinen F, Siebel A. et al. . Treatment of adductor spasticity with BTX-A in children with CP: a randomized, double-blind, placebo-controlled study.  Dev Med Child Neurol. 2006;  48 10-13
  • 32 McNevin NH, Coraci L, Schafer J.. Gait in adolescent cerebral palsy: the effect of partial unweighting.  Arch Phys Med Rehabil. 2000;  81 525-528
  • 33 Morris C.. A review of the efficacy of lower-limb orthoses used for cerebral palsy.  Dev Med Child Neurol. 2002;  44 205-211
  • 34 de Paiva A, Meunier FA, Molgó J. et al. . Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals.  Proc Natl Acad Sci U S A. 1999;  96 3200-3205
  • 35 Palisano R, Rosenbaum PL, Walter S. et al. . Development and reliability of a system to classify gross motor function in children with cerebral palsy.  Dev Med Child Neurol. 1997;  39 214-223
  • 36 Paneth N.. The causes of cerebral palsy. Recent evidence.  Clin Invest Med. 1993;  16 95-102
  • 37 Penn RD, Kroin JS.. Continuous intrathecal baclofen for severe spasticity.  Lancet. 1985;  2 125-127
  • 38 Petruch U, Weber PM, Krageloh-Mann I. The reference and training manual of the SCPE (Surveillance of Cerebral Palsy in Europe).  Neuropediatrics. 2004;  35
  • 39 Polak F, Morton R, Ward C. et al. . Double-blind comparison study of two doses of botulinum toxin A injected into calf muscles in children with hemiplegic cerebral palsy.  Dev Med Child Neurol.. 2002;  44 551-555
  • 40 Reddihough DS, King JA, Coleman GJ. et al. . Functional outcome of botulinum toxin A injections to the lower limbs in cerebral palsy.  Dev Med Child Neurol. 2002;  44 820-827
  • 41 Reime U, Riedel M.. Wirksamkeit dynamischer Sprunggelenk (DAFO) und Fussorthesen (DFO) nach Hylton auf die grobmotorische Funktion zerebral bewegungsgestörter Kinder.  Orthop Prax. 2000;  36 622-628
  • 42 Rosales RL, Bigalke H, Dressler D.. Pharmacology of botulinum toxin: differences between type A preparations.  Eur J Neurol. 2006;  13 2-10
  • 43 Rosenbaum PL, Walter SD, Hanna SE. et al. . Prognosis for gross motor function in cerebral palsy: creation of motor development curves.  JAMA. 2002;  288 1357-1363
  • 44 Schindl MR, Forstner C, Kern H, Hesse S.. Treadmill training with partial body weight support in nonambulatory patients with cerebral palsy.  Arch Phys Med Rehabil. 2000;  81 301-306
  • 45 SCPE. . Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Surveillance of Cerebral Palsy in Europe (SCPE).  Dev Med Child Neurol. 2000;  42 816-824
  • 46 Speth LA, Leffers P, Janssen-Potten YJ, Vles JS.. Botulinum toxin A and upper limb functional skills in hemiparetic cerebral palsy: a randomized trial in children receiving intensive therapy.  Dev Med Child Neurol. 2005;  47 468-473
  • 47 Stanley FJ.. Survival and cerebral palsy in low birthweight infants: implications for perinatal care.  Paediatr Perinat Epidemiol. 1992;  6 298-310
  • 48 Sutherland DH, Kaufman KR, Wyatt MP. et al. . Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy.  Gait Posture. 1999;  10 1-9
  • 49 Taub E, Ramey SL, DeLuca S, Echols K.. Efficacy of constraint-induced movement therapy for children with cerebral palsy with asymmetric motor impairment.  Pediatrics. 2004;  113 305-312
  • 50 Taylor NF, Dodd KJ, Damiano DL.. Progressive resistance exercise in physical therapy: a summary of systematic reviews.  Phys Ther. 2005;  85 1208-1223
  • 51 Ubhi T, Bhakta BB, Ives HL. et al. . Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy.  Arch Dis Child. 2000;  83 481-487
  • 52 Ziv I, Blackburn N, Rang M, Koreska J.. Muscle growth in normal and spastic mice.  Dev Med Child Neurol. 1984;  26 94-99
  • 53 Zuniga RE, Schlicht CR, Abram SE.. Intrathecal baclofen is analgesic in patients with chronic pain.  Anesthesiology. 2000;  92 876-880
  • 54 Zupan V, Gonzalez P, Lacaze-Masmonteil T. et al. . Periventricular leukomalacia: risk factors revisited.  Dev Med Child Neurol. 1996;  38 1061-1067


Dr. med. Urban M. Fietzek

Neurologisches Krankenhaus München

Parzivalplatz 4

80804 München